Closer to a cure for eczema

November 23, 2011

Scientists have found that a strain of yeast implicated in inflammatory skin conditions, including eczema, can be killed by certain peptides and could potentially provide a new treatment for these debilitating skin conditions. This research is published today in the Society for Applied Microbiology's journal, Letters in Applied Microbiology.

20% of children in the UK suffer from atopic eczema and whilst this usually clears up in adolescence, 7% of adults will continue to suffer throughout their lifetime. Furthermore, this type of eczema, characterized by dry, itchy, flaking skin, is increasing in prevalence. Whilst the cause of eczema remains unknown, one known trigger factor is the Malassezia sympodialis.

This strain of yeast is one of the most common skin yeasts in both healthy individuals and those suffering from eczema. The skin barrier is more fragile and often broken in those suffering from such skin conditions, and this allows the yeast to cause infection which then further exacerbates the condition. Scientists at Karolinska Institute in Sweden looked for a way to kill Malassezia sympodialis without harming healthy .

The researchers looked at the effect on the yeast of 21 peptides which had either; cell-penetrating or . Cell-penetrating peptides are often investigated as drug delivery vectors and are able to cross the , although the exact mechanism for this is unknown. , on the other hand, are and kill many different types of microbe including some bacteria, fungi and viruses.

Tina Holm and her colleagues at Stockholm University and Karolinska Institute, added these different peptides types to separate yeast colonies and assessed the toxicity of each peptide type to the yeast. They found that six of the 21 peptides they tested successfully killed the yeast without damaging the membrane of keratinocytes, .

Tina commented "Many questions remain to be solved before these peptides can be used in humans. However, the appealing combination of being toxic to the yeast at low concentrations whilst sparing human cells makes them very promising as antifungal agents. We hope that these peptides in the future can be used to ease the symptoms of patients suffering from atopic eczema and significantly increase their quality of life."

The next step will be to further examine the mechanism(s) used by the peptides to kill yeast cells, in order to develop a potential treatment for eczema and other skin conditions.

More information: Cell-penetrating peptides as antifungals towards Malassezia sympodialis. T. Holm, J. Bruchmann, A. Scheynius, Ü. Langel. Letters in Applied Microbiology DOI. 10.1111/j.1472-765X.2011.03168.x

Related Stories

Recommended for you

A sodium surprise: Engineers find unexpected result during cardiac research

July 20, 2017
Irregular heartbeat—or arrhythmia—can have sudden and often fatal consequences. A biomedical engineering team at Washington University in St. Louis examining molecular behavior in cardiac tissue recently made a surprising ...

Want to win at sports? Take a cue from these mighty mice

July 20, 2017
As student athletes hit training fields this summer to gain the competitive edge, a new study shows how the experiences of a tiny mouse can put them on the path to winning.

Engineered liver tissue expands after transplant

July 19, 2017
Many diseases, including cirrhosis and hepatitis, can lead to liver failure. More than 17,000 Americans suffering from these diseases are now waiting for liver transplants, but significantly fewer livers are available.

Lunatic Fringe gene plays key role in the renewable brain

July 19, 2017
The discovery that the brain can generate new cells - about 700 new neurons each day - has triggered investigations to uncover how this process is regulated. Researchers at Baylor College of Medicine and Jan and Dan Duncan ...

'Smart' robot technology could give stroke rehab a boost

July 19, 2017
Scientists say they have developed a "smart" robotic harness that might make it easier for people to learn to walk again after a stroke or spinal cord injury.

New animal models for hepatitis C could pave the way for a vaccine

July 19, 2017
They say that an ounce of prevention is worth a pound of cure. In the case of hepatitis C—a disease that affects nearly 71 million people worldwide, causing cirrhosis and liver cancer if left untreated—it might be worth ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.